## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER:** 

214985Orig1s000

## **OFFICER/EMPLOYEE LIST**

MEMORANDUM DEPARTMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE

FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

**DATE:** January 7, 2022

**TO:** Administrative file for NDA 214985

**FROM:** Jasmeet (Mona) Kalsi, Regulatory Health Project Manager

Division of Psychiatry, Office of Neuroscience

**SUBJECT:** Officer/Employee List for NDA 214985

**APPLICATION/DRUG:** NDA 214985, Quviviq (daridorexant) tablets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Amspacher, Valerie

Atrakchi, Aisar H

Balimane, Praveen

Bernheimer, Timothy

Bewernitz, Michael

Bhattaram, Atul

Chiou, Grace

Dave, Kaushalkumar

Fischer, Bernard

Freed, Lois

Harbourt, Kelly

Holmes, Loretta

Horn, Pamela

Hutchins, Shawna

Ju, Jing (Julia)

Kolejian, Sevan

Lin, Karl K

Liu, Jinzhong

Miao, Zhuang

Moukhtara, Aline

Nguyen, Phuong B

Potter, Andrew

Radin, Rose

Shan, Zhixing

Sharma, Vishnu

Stone, Kelly Wu, Ta-Chen Yang, Peiling Yao, Jia Yaseen, Zimri Zhuang, Luning (Ada)

This is a representation of an electronic record that was signed
electronically. Following this are manifestations of any and all
electronic signatures for this electronic record.

\_\_\_\_\_

/s/

JASMEET K KALSI 01/07/2022 03:26:32 PM